Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.
| Revenue (TTM) | $150.72M |
| Gross Profit (TTM) | $99.93M |
| EBITDA | $6.29M |
| Operating Margin | -0.07% |
| Return on Equity | -12.00% |
| Return on Assets | -1.91% |
| Revenue/Share (TTM) | $2.28 |
| Book Value | $1.47 |
| Price-to-Book | 1.49 |
| Price-to-Sales (TTM) | 0.97 |
| EV/Revenue | 1.376 |
| EV/EBITDA | 267.32 |
| Quarterly Earnings Growth (YoY) | 200.00% |
| Quarterly Revenue Growth (YoY) | -2.50% |
| Shares Outstanding | $72.09M |
| Float | $16.77M |
| % Insiders | 42.14% |
| % Institutions | 63.38% |
Volatility is currently expanding
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. ("AirSculpt" or the "Company") (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
AirSculpt Technologies, Inc. (AIRS) Q2 2026 Earnings Call Transcript
AirSculpt Technologies NASDAQ: AIRS reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AIRS and any ticker you trade — then tracks every position and per-strategy win rate.
